BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
317.73
-2.41 (-0.75%)
As of 10:11AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close320.14
Open319.60
Bid319.150 x 1800
Ask319.130 x 900
Day's Range317.35 - 320.50
52 Week Range249.17 - 388.67
Volume144,764
Avg. Volume1,284,098
Market Cap64.018B
Beta (3Y Monthly)1.99
PE Ratio (TTM)20.77
EPS (TTM)15.297
Earnings DateJan 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est388.35
Trade prices are not sourced from all markets
  • Zacks2 hours ago

    5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019

    The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.

  • Do Analysts See Any Upside for Biogen Stock?
    Market Realist3 hours ago

    Do Analysts See Any Upside for Biogen Stock?

    Of the 29 analysts covering Biogen (BIIB), 20 have given it “buy” or higher ratings, and nine have given it “hold” ratings.

  • Taking Stock of Biogen’s Recent Performance
    Market Realist21 hours ago

    Taking Stock of Biogen’s Recent Performance

    Biogen’s (BIIB) core growth areas include multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, and neuromuscular disorders. It’s also focused on areas such as pain, ophthalmology, neuropsychiatry, and acute neurology.

  • A Closer Look at Biogen’s Gross Margin Trends
    Market Realist21 hours ago

    A Closer Look at Biogen’s Gross Margin Trends

    In 2018 and 2019, Biogen (BIIB) is expected to generate revenues of $13.31 billion and $13.66 billion, respectively, compared to $12.27 billion in 2017.

  • The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
    Zacksyesterday

    The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

    The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

  • Zacks2 days ago

    Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

    A low key week for the biotech sector with focus on regular pipeline updates.

  • Do Analysts See Any Upside for Regeneron Stock?
    Market Realist2 days ago

    Do Analysts See Any Upside for Regeneron Stock?

    Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.” Their mean rating for Regeneron stock is 2.58, and their target price is $426.05, implying a 12.8% upside for the stock based on its December 10 closing price of $377.59.

  • What Regeneron Pharmaceuticals’ Bottom Line Indicates
    Market Realist2 days ago

    What Regeneron Pharmaceuticals’ Bottom Line Indicates

    In this year’s third quarter, Regeneron Pharmaceuticals’ (REGN) interest expenses rose YoY (year-over-year) to $7.49 million from $6.18 million, and its net other income rose YoY to $16.43 million from $11.86 million. Its income tax expenses fell YoY to $41.21 million from $177.29 million.

  • The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

    The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

  • Understanding Regeneron Pharmaceuticals’ Operational Performance
    Market Realist3 days ago

    Understanding Regeneron Pharmaceuticals’ Operational Performance

    In the third quarter of this year, Regeneron Pharmaceuticals’ (REGN) selling, general, and administrative expenses rose YoY (year-over-year) to $369.23 million from $306.77 million, primarily due to a higher employee headcount. Meanwhile, its R&D (research and development) expenses rose YoY to $556.97 million from $529.75 million. It had R&D expenses of $2.03 billion and $2.23 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $2.07 billion in fiscal 2017.

  • Regeneron Pharmaceuticals’ Gross Margin Trends
    Market Realist3 days ago

    Regeneron Pharmaceuticals’ Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017. Meanwhile, peers Amgen (AMGN), Biogen (BIIB), and Johnson & Johnson (JNJ) are expected to have revenue of $23.36 billion, $13.31 billion, and $81.35 billion, respectively, in fiscal 2018. Regeneron’s cash per share is $20.14, while Amgen’s, Biogen’s, and Johnson & Johnson’s cash per share is $45.17, $21.31, and $7.20, respectively.

  • Zacks3 days ago

    4 Biotech Stocks Investors Can Add to Their Portfolio in 2019

    Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.

  • GlobeNewswire8 days ago

    Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data

    Biogen Inc (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) announced today that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations. ALS with SOD1 mutations is a subtype of familial ALS and accounts for approximately two percent of all ALS cases.

  • FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
    Zacks10 days ago

    FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101

    The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.

  • AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018
    Zacks11 days ago

    AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018

    AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.

  • Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar
    Investor's Business Daily14 days ago

    Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar

    Pfizer on Friday joined a slew of pharmaceutical stocks with licensing deals to launch a Humira biosimilar under a deal with AbbVie.

  • How Much Upside Wall Street Sees in Sangamo Stock
    Market Realist14 days ago

    How Much Upside Wall Street Sees in Sangamo Stock

    In November, of the total eight analysts covering Sangamo Therapeutics (SGMO), five have given the stock a “buy” or higher rating and three analysts have given it a “hold” rating. The mean rating for Sangamo Therapeutics stock is 2.0 with a target price of $22.71, implying an upside potential of 90.5% over the closing price of $11.92 on November 29.

  • Taking Stock of Sangamo’s Financial Performance
    Market Realist14 days ago

    Taking Stock of Sangamo’s Financial Performance

    Sangamo Therapeutics (SGMO) focuses on developing and bringing to market novel genomic therapies. Its genome editing and gene regulation technology platform is enabled by engineering transcription factors called zinc finger DNA-binding proteins, which can increase or decrease gene expression or gene regulation.

  • Analyzing Sangamo Therapeutics’ Operational Performance
    Market Realist14 days ago

    Analyzing Sangamo Therapeutics’ Operational Performance

    Sangamo Therapeutics (SGMO) incurred general and administrative expenses of $10.99 million in the third quarter of 2018, compared with $6.42 million in the third quarter of 2017. The fiscal 2018 research and development expenses for peers Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) are expected at $3.52 billion, $2.48 billion, and $3.71 billion, respectively. Sangamo Therapeutics’ net interest and other income grew from $681,000 in the third quarter of 2017 to $3.4 million in the latest quarter.

  • How To Trade Growth Stocks: Why Biogen Fell Below Its Buy Point On Breakout Day But Still Won Big
    Investor's Business Daily15 days ago

    How To Trade Growth Stocks: Why Biogen Fell Below Its Buy Point On Breakout Day But Still Won Big

    Should you immediately sell a stock when it breaks out but closes beneath the proper buy point? Not always. Here are some tips on when to sit tight and when to bail early.

  • Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma
    Zacks15 days ago

    Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma

    Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.

  • United Therapeutics: A Financial Overview in November
    Market Realist18 days ago

    United Therapeutics: A Financial Overview in November

    United Therapeutics (UTHR) generated net revenues of $412.7 million in the third quarter—compared to $445.5 million during the third quarter of 2017, which reflected a decline of ~7% YoY (year-over-year). United Therapeutics’ net revenues during the first nine months of 2018 were $1.25 billion—compared to $1.26 billion during the same period in 2017, which reflected a decline of 1% YoY.

  • United Therapeutics: Recent Developments and Analysts’ Ratings
    Market Realist18 days ago

    United Therapeutics: Recent Developments and Analysts’ Ratings

    On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA). According to the agreement, Arena Pharmaceuticals will provide United Therapeutics exclusive worldwide rights to develop, manufacture, and commercialize its investigational drug, ralinepag, to treat individuals with pulmonary arterial hypertension. Currently, ralinepag is in its Phase 3 clinical stage.